EVALUATION OF CLINICAL EFFECTIVENESS OF THE DRUG SILIOSTIN IN BROILER CHICKEN DYSCHONDROPLASIA

Abstract

An experiment was conducted at the poultry farm "Ivanov A. S." to study the clinical effectiveness of the new osteotropic drug Siliostin in broiler chicken dischondroplasia. Siliostin is a complex pharmaceutical composition containing sources of organosilicon and inorganic compounds, flavonoids, organic acids, vitamins, and a range of osteotropic macro and microelements. Two groups of Cobb-500 crossbred broiler chickens were formed for the experiment experimental and control (n = 60). Over 21 days, the birds in the experimental group received Siliostin at a dose of 2% of the mass of consumed complete feed, while the control group chickens were fed only on the primary ration feeds. The therapeutic effectiveness of Siliostin was evaluated based on criteria such as clinical condition, flock integrity, body weight, and serum blood biochemistry indicators. It was established that the use of the drug in cases of clinical manifestation of dischondroplasia in broiler chickens contributes to the improvement of the physiological condition of sick birds, normalisation of indicators of biochemical homeostasis, and also has a positive effect on feed activity and intensive body weight gain. Moreover, after the end of the drug administration period and until the completion of the production cycle (60 days), the positive dynamics in the parameters mentioned above were maintained, and no repeated cases of dischondroplasia were observed in the experimental group of broilers.